FDA-Approved Ovarian Cancer Treatments- MPR

FDA-Approved Ovarian Cancer Treatments

FDA-APPROVED OVARIAN CANCER TREATMENTS
Generic	Brand	Strength	Form	Usual Dose
Alkylating agent
carboplatin	—	10mg/ mL	soln for IV infusion	Advanced ovarian cancer (previously untreated): 300mg/m² on Day 1 every 4wks for 6 cycles Recurrent ovarian cancer: 360mg/m² on Day 1 every 4wks
cisplatin	—	1mg/mL	soln for IV infusion after dilution	75–100mg/m² IV per cycle once every 3–4wks on Day 1
cisplatin	—	50mg/vial	pwd for IV infusion after reconstitution and dilution	75–100mg/m² IV per cycle once every 3–4wks on Day 1
cyclophos– phamide	—	25mg, 50mg	tabs	1–5mg/kg/day
cyclophos– phamide	—	500mg, 1g, 2g	pwd for inj after reconsti– tution	40–50mg/kg in divided doses over 2–5 days or 10–15mg/kg every 7–10 days or 3–5mg/kg twice weekly
melphalan	—	2mg	scored tabs	0.2mg/kg/day for 5 days; repeat every 4–5wks
thiotepa	—	15mg	pwd for IV, intravesical, or intracavitary admini– stration after reconsti– tution	0.3–0.4mg/kg IV once every 1–4wks
Antibiotics (cytotoxic)
doxorubicin	—	10mg, 20mg, 50mg	pwd for IV inj after reconsti– tution	Monotherapy: 60–75mg/m² every 21 days Combination therapy: 40–60mg/m² every 21 to 28 days
doxorubicin	—	2mg/mL	soln for IV inj
doxorubicin (liposomal)	Doxil	2mg/mL	dispersion for IV infusion after dilution	50mg/m² once every 4wks; continue for ≥4 cycles as tolerated. Initial rate: 1mg/min; may increase rate to complete infusion over 1hr if no infusion reactions occur.
Antimetabolite
gemcitabine	—	200mg, 1g, 2g	pwd for IV infusion after reconsti– tution	1000mg/m² on Days 1 and 8 of each 21-day cycle; give with carboplatin AUC 4 administered on Day 1 after gemcitabine
Antimicrotubule agents
paclitaxel	—	6mg/mL	soln for IV infusion after dilution	Previously untreated ovarian cancer: 175mg/m² IV over 3hrs + cisplatin; or 135mg/m² IV over 24hrs + cisplatin; repeat every 3wks Previously treated ovarian cancer: 135mg/m² or 175mg/m² over 3hrs every 3wks
FOLATE-RECEPTOR ALPHA-DIRECTED ANTIBODY-DRUG CONJUGATE
mirvetuximab soravtansine-gynx	Elahere	5mg/mL	soln for IV infusion after dilution	Folate receptor-alpha positive epithelial ovarian cancer: 6mg/kg (adjusted ideal body weight)once every 3wks (21-day cycle) until disease progression or unacceptable toxicity. Infuse initially at a rate of 1mg/min; may increase to 3mg/min if well tolerated after 30mins, then to 5mg/min after next 30mins (max rate).
POLY (ADP-RIBOSE) POLYMERASE INHIBITOR
niraparib	Zejula	100mg	caps	First-line maintenance of advanced ovarian cancer: start within 12wks after most recent platinum-containing regimen; (patients <77kg or with platelets <150000/μL): 200mg once daily; (patients ≥77kg and platelets ≥150000/μL): 300mg once daily. Maintenance of recurrent ovarian cancer: start within 8wks after most recent platinum-containing regimen; 300mg once daily. All: continue until disease progression or unacceptable toxicity.
olaparib	Lynparza	100mg, 150mg	tabs	300mg twice daily. First-line maintenance of BRCA-mutated or HRD-positive advanced ovarian: continue until disease progression, unacceptable toxicity, or completion of 2yrs of treatment. Discontinue if complete response at 2yrs; may treat beyond 2yrs in those with evidence of disease if provider can derive further benefit from continuous treatment. Maintenance of recurrent ovarian or germline BRCA-mutated advanced ovarian: continue until disease progression or unacceptable toxicity. In combination with bevacizumab: give bevacizumab (15mg/kg every 3wks) for total of 15mos (see full labeling).
rucaparib	Rubraca	200mg, 250mg, 300mg	tabs	Deleterious BRCA-mutated recurrent epithelial ovarian cancer: 600mg twice daily until disease progression or unacceptable toxicity
Topoisomerase inhibitor
topotecan	Hycamtin	4mg	pwd for IV infusion after reconsti– tution and dilution	1.5mg/m² daily for 5 consecutive days starting on Day 1 of a 21-day cycle
Vascular Endothelial Growth Factor (VEGF) Inhibitor
bevacizumab	Avastin	100mg, 400mg	soln for IV infusion after dilution	Recurrent ovarian cancer (platinum-resistant): 10mg/kg every 2wks with either paclitaxel, pegylated liposomal doxorubicin, or topotecan (weekly); or, 15mg/kg every 3wks with topotecan (every 3wks); (platinum-sensitive): 15mg/kg every 3wks with carboplatin/ paclitaxel for 6–8 cycles or with carboplatin/gemcitabine for 6–10 cycles; followed by bevacizumab 15mg/kg every 3wks as a single agent until disease progression. Stage III/IV ovarian cancer after initial surgical resection: 15mg/kg every 3wks with carboplatin/ paclitaxel for up to 6 cycles; followed by bevacizumab 15mg/kg every 3wks as a single agent, for a total of up to 22 cycles or until disease progression, whichever occurs first.
	Vegzelma
	Mvasi
	Zirabev
	Alymsys	100mg, 400mg	soln for IV infusion after dilution	Recurrent epithelial ovarian cancer (platinum-resistant): 10mg/kg every 2wks with either paclitaxel, pegylated liposomal doxorubicin, or topotecan (weekly); or, 15mg/kg every 3wks with topotecan (every 3wks).
NOTES
Not an inclusive list of medications and/or doses. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling. (Rev. 12/2023)

Want to read more?